▶ 調査レポート

上衣腫の世界市場(~2026年)

• 英文タイトル:Global Ependymoma Market Size, Status and Forecast 2020-2026

QYResearchが調査・発行した産業分析レポートです。上衣腫の世界市場(~2026年) / Global Ependymoma Market Size, Status and Forecast 2020-2026 / MRC2-11QY11867資料のイメージです。• レポートコード:MRC2-11QY11867
• 出版社/出版日:QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、90ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:ヘルスケア
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User¥865,800 (USD5,850)▷ お問い合わせ
  Enterprise License¥1,154,400 (USD7,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料は上衣腫のグローバル市場について調査・分析したレポートです。種類別(粘液乳頭状上衣腫、上衣下腫、古典的上衣腫、退形成性上衣腫)市場規模、用途別(子供、成人)市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別上衣腫の競争状況、市場シェア
・世界の上衣腫市場:種類別市場規模 2015年-2020年(粘液乳頭状上衣腫、上衣下腫、古典的上衣腫、退形成性上衣腫)
・世界の上衣腫市場:種類別市場規模予測 2021年-2026年(粘液乳頭状上衣腫、上衣下腫、古典的上衣腫、退形成性上衣腫)
・世界の上衣腫市場:用途別市場規模 2015年-2020年(子供、成人)
・世界の上衣腫市場:用途別市場規模予測 2021年-2026年(子供、成人)
・北米の上衣腫市場分析:米国、カナダ
・ヨーロッパの上衣腫市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの上衣腫市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の上衣腫市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの上衣腫市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Eli Lilly、Astellas、DNAtrix、Advantagene、Burzynski Research Institute、Direct Therapeutics、Cellectar Biosciences、Amgen、Boehringer Ingelheim、Bristol-Myers Squibb、Celgene、Novartis、NewLink Genetics
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Ependymoma are tissue-based tumors arising from the cells lining the ventricles and central canal within the spinal cord.
Like many tumor types, the exact cause of ependymoma is not known. Unknown causes and lucrative revenue prospects have grabbed attention from big drug makers and thus the market is expected to exhibit significant growth in market value over the forecast years.

Market Analysis and Insights: Global Ependymoma Market
The global Ependymoma market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Ependymoma Scope and Market Size
Ependymoma market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Ependymoma market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Eli Lilly
Astellas
DNAtrix
Advantagene
Burzynski Research Institute
Direct Therapeutics
Cellectar Biosciences
Amgen
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Novartis
NewLink Genetics

Market segment by Type, the product can be split into
Myxopapillary Ependymomas
Subependymomas
Classic Ependymomas
Anaplastic Ependymomas
Market segment by Application, split into
Children
Adults

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Ependymoma Revenue
1.4 Market by Type
1.4.1 Global Ependymoma Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Myxopapillary Ependymomas
1.4.3 Subependymomas
1.4.4 Classic Ependymomas
1.4.5 Anaplastic Ependymomas
1.5 Market by Application
1.5.1 Global Ependymoma Market Share by Application: 2020 VS 2026
1.5.2 Children
1.5.3 Adults
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Ependymoma Market Perspective (2015-2026)
2.2 Global Ependymoma Growth Trends by Regions
2.2.1 Ependymoma Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Ependymoma Historic Market Share by Regions (2015-2020)
2.2.3 Ependymoma Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Ependymoma Market Growth Strategy
2.3.6 Primary Interviews with Key Ependymoma Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Ependymoma Players by Market Size
3.1.1 Global Top Ependymoma Players by Revenue (2015-2020)
3.1.2 Global Ependymoma Revenue Market Share by Players (2015-2020)
3.1.3 Global Ependymoma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Ependymoma Market Concentration Ratio
3.2.1 Global Ependymoma Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Ependymoma Revenue in 2019
3.3 Ependymoma Key Players Head office and Area Served
3.4 Key Players Ependymoma Product Solution and Service
3.5 Date of Enter into Ependymoma Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Ependymoma Historic Market Size by Type (2015-2020)
4.2 Global Ependymoma Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Ependymoma Market Size by Application (2015-2020)
5.2 Global Ependymoma Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Ependymoma Market Size (2015-2020)
6.2 Ependymoma Key Players in North America (2019-2020)
6.3 North America Ependymoma Market Size by Type (2015-2020)
6.4 North America Ependymoma Market Size by Application (2015-2020)

7 Europe
7.1 Europe Ependymoma Market Size (2015-2020)
7.2 Ependymoma Key Players in Europe (2019-2020)
7.3 Europe Ependymoma Market Size by Type (2015-2020)
7.4 Europe Ependymoma Market Size by Application (2015-2020)

8 China
8.1 China Ependymoma Market Size (2015-2020)
8.2 Ependymoma Key Players in China (2019-2020)
8.3 China Ependymoma Market Size by Type (2015-2020)
8.4 China Ependymoma Market Size by Application (2015-2020)

9 Japan
9.1 Japan Ependymoma Market Size (2015-2020)
9.2 Ependymoma Key Players in Japan (2019-2020)
9.3 Japan Ependymoma Market Size by Type (2015-2020)
9.4 Japan Ependymoma Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Ependymoma Market Size (2015-2020)
10.2 Ependymoma Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Ependymoma Market Size by Type (2015-2020)
10.4 Southeast Asia Ependymoma Market Size by Application (2015-2020)

11 India
11.1 India Ependymoma Market Size (2015-2020)
11.2 Ependymoma Key Players in India (2019-2020)
11.3 India Ependymoma Market Size by Type (2015-2020)
11.4 India Ependymoma Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Ependymoma Market Size (2015-2020)
12.2 Ependymoma Key Players in Central & South America (2019-2020)
12.3 Central & South America Ependymoma Market Size by Type (2015-2020)
12.4 Central & South America Ependymoma Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Eli Lilly
13.1.1 Eli Lilly Company Details
13.1.2 Eli Lilly Business Overview
13.1.3 Eli Lilly Ependymoma Introduction
13.1.4 Eli Lilly Revenue in Ependymoma Business (2015-2020))
13.1.5 Eli Lilly Recent Development
13.2 Astellas
13.2.1 Astellas Company Details
13.2.2 Astellas Business Overview
13.2.3 Astellas Ependymoma Introduction
13.2.4 Astellas Revenue in Ependymoma Business (2015-2020)
13.2.5 Astellas Recent Development
13.3 DNAtrix
13.3.1 DNAtrix Company Details
13.3.2 DNAtrix Business Overview
13.3.3 DNAtrix Ependymoma Introduction
13.3.4 DNAtrix Revenue in Ependymoma Business (2015-2020)
13.3.5 DNAtrix Recent Development
13.4 Advantagene
13.4.1 Advantagene Company Details
13.4.2 Advantagene Business Overview
13.4.3 Advantagene Ependymoma Introduction
13.4.4 Advantagene Revenue in Ependymoma Business (2015-2020)
13.4.5 Advantagene Recent Development
13.5 Burzynski Research Institute
13.5.1 Burzynski Research Institute Company Details
13.5.2 Burzynski Research Institute Business Overview
13.5.3 Burzynski Research Institute Ependymoma Introduction
13.5.4 Burzynski Research Institute Revenue in Ependymoma Business (2015-2020)
13.5.5 Burzynski Research Institute Recent Development
13.6 Direct Therapeutics
13.6.1 Direct Therapeutics Company Details
13.6.2 Direct Therapeutics Business Overview
13.6.3 Direct Therapeutics Ependymoma Introduction
13.6.4 Direct Therapeutics Revenue in Ependymoma Business (2015-2020)
13.6.5 Direct Therapeutics Recent Development
13.7 Cellectar Biosciences
13.7.1 Cellectar Biosciences Company Details
13.7.2 Cellectar Biosciences Business Overview
13.7.3 Cellectar Biosciences Ependymoma Introduction
13.7.4 Cellectar Biosciences Revenue in Ependymoma Business (2015-2020)
13.7.5 Cellectar Biosciences Recent Development
13.8 Amgen
13.8.1 Amgen Company Details
13.8.2 Amgen Business Overview
13.8.3 Amgen Ependymoma Introduction
13.8.4 Amgen Revenue in Ependymoma Business (2015-2020)
13.8.5 Amgen Recent Development
13.9 Boehringer Ingelheim
13.9.1 Boehringer Ingelheim Company Details
13.9.2 Boehringer Ingelheim Business Overview
13.9.3 Boehringer Ingelheim Ependymoma Introduction
13.9.4 Boehringer Ingelheim Revenue in Ependymoma Business (2015-2020)
13.9.5 Boehringer Ingelheim Recent Development
13.10 Bristol-Myers Squibb
13.10.1 Bristol-Myers Squibb Company Details
13.10.2 Bristol-Myers Squibb Business Overview
13.10.3 Bristol-Myers Squibb Ependymoma Introduction
13.10.4 Bristol-Myers Squibb Revenue in Ependymoma Business (2015-2020)
13.10.5 Bristol-Myers Squibb Recent Development
13.11 Celgene
10.11.1 Celgene Company Details
10.11.2 Celgene Business Overview
10.11.3 Celgene Ependymoma Introduction
10.11.4 Celgene Revenue in Ependymoma Business (2015-2020)
10.11.5 Celgene Recent Development
13.12 Novartis
10.12.1 Novartis Company Details
10.12.2 Novartis Business Overview
10.12.3 Novartis Ependymoma Introduction
10.12.4 Novartis Revenue in Ependymoma Business (2015-2020)
10.12.5 Novartis Recent Development
13.13 NewLink Genetics
10.13.1 NewLink Genetics Company Details
10.13.2 NewLink Genetics Business Overview
10.13.3 NewLink Genetics Ependymoma Introduction
10.13.4 NewLink Genetics Revenue in Ependymoma Business (2015-2020)
10.13.5 NewLink Genetics Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Ependymoma Key Market Segments
Table 2. Key Players Covered: Ranking by Ependymoma Revenue
Table 3. Ranking of Global Top Ependymoma Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Ependymoma Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Myxopapillary Ependymomas
Table 6. Key Players of Subependymomas
Table 7. Key Players of Classic Ependymomas
Table 8. Key Players of Anaplastic Ependymomas
Table 9. Global Ependymoma Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Ependymoma Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Ependymoma Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Ependymoma Market Share by Regions (2015-2020)
Table 13. Global Ependymoma Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Ependymoma Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Ependymoma Market Growth Strategy
Table 19. Main Points Interviewed from Key Ependymoma Players
Table 20. Global Ependymoma Revenue by Players (2015-2020) (Million US$)
Table 21. Global Ependymoma Market Share by Players (2015-2020)
Table 22. Global Top Ependymoma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ependymoma as of 2019)
Table 23. Global Ependymoma by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Ependymoma Product Solution and Service
Table 26. Date of Enter into Ependymoma Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Ependymoma Market Size by Type (2015-2020) (Million US$)
Table 29. Global Ependymoma Market Size Share by Type (2015-2020)
Table 30. Global Ependymoma Revenue Market Share by Type (2021-2026)
Table 31. Global Ependymoma Market Size Share by Application (2015-2020)
Table 32. Global Ependymoma Market Size by Application (2015-2020) (Million US$)
Table 33. Global Ependymoma Market Size Share by Application (2021-2026)
Table 34. North America Key Players Ependymoma Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Ependymoma Market Share (2019-2020)
Table 36. North America Ependymoma Market Size by Type (2015-2020) (Million US$)
Table 37. North America Ependymoma Market Share by Type (2015-2020)
Table 38. North America Ependymoma Market Size by Application (2015-2020) (Million US$)
Table 39. North America Ependymoma Market Share by Application (2015-2020)
Table 40. Europe Key Players Ependymoma Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Ependymoma Market Share (2019-2020)
Table 42. Europe Ependymoma Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Ependymoma Market Share by Type (2015-2020)
Table 44. Europe Ependymoma Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Ependymoma Market Share by Application (2015-2020)
Table 46. China Key Players Ependymoma Revenue (2019-2020) (Million US$)
Table 47. China Key Players Ependymoma Market Share (2019-2020)
Table 48. China Ependymoma Market Size by Type (2015-2020) (Million US$)
Table 49. China Ependymoma Market Share by Type (2015-2020)
Table 50. China Ependymoma Market Size by Application (2015-2020) (Million US$)
Table 51. China Ependymoma Market Share by Application (2015-2020)
Table 52. Japan Key Players Ependymoma Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Ependymoma Market Share (2019-2020)
Table 54. Japan Ependymoma Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Ependymoma Market Share by Type (2015-2020)
Table 56. Japan Ependymoma Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Ependymoma Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Ependymoma Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Ependymoma Market Share (2019-2020)
Table 60. Southeast Asia Ependymoma Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Ependymoma Market Share by Type (2015-2020)
Table 62. Southeast Asia Ependymoma Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Ependymoma Market Share by Application (2015-2020)
Table 64. India Key Players Ependymoma Revenue (2019-2020) (Million US$)
Table 65. India Key Players Ependymoma Market Share (2019-2020)
Table 66. India Ependymoma Market Size by Type (2015-2020) (Million US$)
Table 67. India Ependymoma Market Share by Type (2015-2020)
Table 68. India Ependymoma Market Size by Application (2015-2020) (Million US$)
Table 69. India Ependymoma Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Ependymoma Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Ependymoma Market Share (2019-2020)
Table 72. Central & South America Ependymoma Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Ependymoma Market Share by Type (2015-2020)
Table 74. Central & South America Ependymoma Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Ependymoma Market Share by Application (2015-2020)
Table 76. Eli Lilly Company Details
Table 77. Eli Lilly Business Overview
Table 78. Eli Lilly Product
Table 79. Eli Lilly Revenue in Ependymoma Business (2015-2020) (Million US$)
Table 80. Eli Lilly Recent Development
Table 81. Astellas Company Details
Table 82. Astellas Business Overview
Table 83. Astellas Product
Table 84. Astellas Revenue in Ependymoma Business (2015-2020) (Million US$)
Table 85. Astellas Recent Development
Table 86. DNAtrix Company Details
Table 87. DNAtrix Business Overview
Table 88. DNAtrix Product
Table 89. DNAtrix Revenue in Ependymoma Business (2015-2020) (Million US$)
Table 90. DNAtrix Recent Development
Table 91. Advantagene Company Details
Table 92. Advantagene Business Overview
Table 93. Advantagene Product
Table 94. Advantagene Revenue in Ependymoma Business (2015-2020) (Million US$)
Table 95. Advantagene Recent Development
Table 96. Burzynski Research Institute Company Details
Table 97. Burzynski Research Institute Business Overview
Table 98. Burzynski Research Institute Product
Table 99. Burzynski Research Institute Revenue in Ependymoma Business (2015-2020) (Million US$)
Table 100. Burzynski Research Institute Recent Development
Table 101. Direct Therapeutics Company Details
Table 102. Direct Therapeutics Business Overview
Table 103. Direct Therapeutics Product
Table 104. Direct Therapeutics Revenue in Ependymoma Business (2015-2020) (Million US$)
Table 105. Direct Therapeutics Recent Development
Table 106. Cellectar Biosciences Company Details
Table 107. Cellectar Biosciences Business Overview
Table 108. Cellectar Biosciences Product
Table 109. Cellectar Biosciences Revenue in Ependymoma Business (2015-2020) (Million US$)
Table 110. Cellectar Biosciences Recent Development
Table 111. Amgen Business Overview
Table 112. Amgen Product
Table 113. Amgen Company Details
Table 114. Amgen Revenue in Ependymoma Business (2015-2020) (Million US$)
Table 115. Amgen Recent Development
Table 116. Boehringer Ingelheim Company Details
Table 117. Boehringer Ingelheim Business Overview
Table 118. Boehringer Ingelheim Product
Table 119. Boehringer Ingelheim Revenue in Ependymoma Business (2015-2020) (Million US$)
Table 120. Boehringer Ingelheim Recent Development
Table 121. Bristol-Myers Squibb Company Details
Table 122. Bristol-Myers Squibb Business Overview
Table 123. Bristol-Myers Squibb Product
Table 124. Bristol-Myers Squibb Revenue in Ependymoma Business (2015-2020) (Million US$)
Table 125. Bristol-Myers Squibb Recent Development
Table 126. Celgene Company Details
Table 127. Celgene Business Overview
Table 128. Celgene Product
Table 129. Celgene Revenue in Ependymoma Business (2015-2020) (Million US$)
Table 130. Celgene Recent Development
Table 131. Novartis Company Details
Table 132. Novartis Business Overview
Table 133. Novartis Product
Table 134. Novartis Revenue in Ependymoma Business (2015-2020) (Million US$)
Table 135. Novartis Recent Development
Table 136. NewLink Genetics Company Details
Table 137. NewLink Genetics Business Overview
Table 138. NewLink Genetics Product
Table 139. NewLink Genetics Revenue in Ependymoma Business (2015-2020) (Million US$)
Table 140. NewLink Genetics Recent Development
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Ependymoma Market Share by Type: 2020 VS 2026
Figure 2. Myxopapillary Ependymomas Features
Figure 3. Subependymomas Features
Figure 4. Classic Ependymomas Features
Figure 5. Anaplastic Ependymomas Features
Figure 6. Global Ependymoma Market Share by Application: 2020 VS 2026
Figure 7. Children Case Studies
Figure 8. Adults Case Studies
Figure 9. Ependymoma Report Years Considered
Figure 10. Global Ependymoma Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Ependymoma Market Share by Regions: 2020 VS 2026
Figure 12. Global Ependymoma Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Ependymoma Market Share by Players in 2019
Figure 15. Global Top Ependymoma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ependymoma as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Ependymoma Revenue in 2019
Figure 17. North America Ependymoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Ependymoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Ependymoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Ependymoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Ependymoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Ependymoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Ependymoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed